Pregabalin Capsule
Product Images NDC 71610-845

Product Visual Gallery

This gallery contains 15 technical images submitted to the FDA as part of the official labeling for Pregabalin (NDC 71610-845). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Aphena Pharma Solutions - Tennessee, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Bottle Label 150 mg (71610 0845 30)

Pregabalin 150 mg capsule label showing packaging for 30 capsules by Aphena Pharma Solutions - Tennessee, LLC. The label includes storage instructions, manufacturer details (MSN Laboratories Private Limited, Telangana, India), and regulatory warnings. It lists the NDC number as 71610-845-30 and specifies oral administration.*

FDA Label Image

Aphena Pharma Solutions (TN)

FDA Label Image

Equation (Pregabain Gault Equation)

The image shows a formula for calculating creatinine clearance (CLCr). It includes variables for age in years, weight in kilograms, serum creatinine in mg/dL, and a multiplier of 0.85 specifically for female patients. The formula is presented in a mathematical fraction format.*

FDA Label Image

Fig-01 (Pregabalin Figure 01)

A line graph illustrating the percent of patients improved versus percent improvement in pain from baseline for Pregabalin and placebo. Four lines represent Pregabalin at 200 mg, 100 mg, and 25 mg three times a day, compared to placebo, showing trends in pain improvement across different dose levels.*

FDA Label Image

Fig-02 (Pregabalin Figure 02)

A graph showing the percent of patients improved versus percent improvement in pain from baseline. It compares two groups: Pregabalin 100 mg three times a day (dashed line) and placebo (dotted line). The graph illustrates higher percentages of patients improved at various pain improvement levels for Pregabalin compared to placebo.*

FDA Label Image

Fig-03 (Pregabalin Figure 03)

A line graph depicting percent improvement in pain from baseline on the x-axis against percent of patients improved on the y-axis. Four lines represent Pregabalin dosed at 300 mg, 150 mg, 75 mg twice daily, and placebo. Higher doses of Pregabalin show greater percentages of patient improvement compared to placebo.*

FDA Label Image

Fig-04 (Pregabalin Figure 04)

A cumulative distribution plot showing percent improvement in pain from baseline on the x-axis and percent of patients improved on the y-axis. The graph compares three groups: Pregabalin 200 mg three times a day, Pregabalin 100 mg three times a day, and placebo, with separate lines for each treatment group.*

FDA Label Image

Fig-05 (Pregabalin Figure 05)

A line graph showing the percent of patients improved versus percent improvement in pain from baseline, comparing Pregabalin 100 mg three times a day (dashed line), Pregabalin 50 mg three times a day (solid line), and placebo (dotted line). The graph illustrates patient response rates to different dosages of Pregabalin and placebo over various levels of pain improvement.*

FDA Label Image

Fig-06 (Pregabalin Figure 06)

Bar chart showing responder rates (%) from two studies (E1 and E3) evaluating oral Pregabalin dosed at various levels and frequencies, compared to placebo. Study E1 includes doses ranging from 50 to 600 mg per day administered twice daily (BID), and Study E3 compares placebo with 600 mg daily doses BID and TID. The chart indicates increasing responder rates with higher Pregabalin doses.*

FDA Label Image

Fig-07 (Pregabalin Figure 07)

A dose-response line graph depicting seizure reduction as median percentage change from baseline for different Pregabalin dosing regimens. The x-axis shows dose in mg/day (0, 50, 150, 300, 600), and the y-axis shows seizure reduction. Four groups are indicated: Stukly E1BID (circle), Stukly E2BID (square), Stukly E3BID (triangle filled), and Stukly E3TID (triangle hollow). P-values for significance are displayed at various points.*

FDA Label Image

Fig-09 (Pregabalin Figure 09)

A cumulative distribution curve graph depicting the percent improvement in pain from baseline on the x-axis versus the percent of patients improved on the y-axis. The graph compares four groups: Pregabalin 600 mg, 450 mg, and 300 mg daily doses, and placebo, with distinct line styles representing each group.*

FDA Label Image

Fig-10 (Pregabalin Figure 10)

A Kaplan-Meier survival curve comparing the estimated percentage of subjects without loss of treatment response (LTR) over 180 days between Pregabalin and Placebo groups. The y-axis shows the estimated percentage without LTR from 0% to 100%, and the x-axis shows study duration in days from 0 to 180. Two lines are shown: a solid line for Pregabalin and a dashed line for Placebo.*

FDA Label Image

Fig-11 (Pregabalin Figure 11)

A line graph comparing the percent of subjects improved over a range of percent improvement from baseline to Week 12 using a BOCF method. The solid line represents Pregabalin, and the dashed line represents Placebo. The vertical axis shows the percent of subjects improved from 0 to 100%, and the horizontal axis shows percent improved from baseline in increments up to 100%. Pregabalin shows higher percentages of improvement than placebo across this range.*

FDA Label Image

Fig-12 (Pregabalin Figure 12)

A cumulative response curve chart showing the percent of subjects improved on the Y-axis against the percent improved from baseline to Week 16 BOCF on the X-axis. Two lines are plotted: one solid line representing Pregabalin and one dashed line representing Placebo, with the Pregabalin group showing higher percentages of subjects improved across the improvement spectrum.*

FDA Label Image

Str (Pregabalin Structure)

Chemical structure of Pregabalin, showing its molecular arrangement including the amino group, carboxyl group, and side chains consistent with its chemical formula.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.